Italia markets close in 16 minutes

FTSE MIB
34.592,24
-232,77(-0,67%)
Dow Jones
39.856,63
+49,86(+0,13%)
Nasdaq
16.793,22
-1,65(-0,01%)
Nikkei 225
38.946,93
-122,75(-0,31%)
Petrolio
79,32
-0,48(-0,60%)
Bitcoin EUR
64.643,56
+2.869,62(+4,65%)

NVCR Jan 2025 12.500 put

OPR - OPR Prezzo differito. Valuta in USD.

Aggiungi a watchlist

1,2000

0,0000

(0,00%)

In data: 03:26PM EDT. Mercato aperto.

GlobeNewswire
Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
Tumor Treating Fields therapy together with standard of care provided a statistically significant and clinically meaningful 3-month improvement in median overall survival versus standard of care with no added systemic toxicities Tumor Treating Fields therapy together with immune checkpoint inhibitors resulted in an unprecedented 8-month improvement in median overall survival LUNAR is the first phase 3 clinical trial in more than seven years to show a significant extension in overall survival in